April 26, 2022 4:03 pm
Haemair has recently completed a Welsh Government SMARTCymru-supported project on ex-vivo support of organs and tissues. The scope of the project is described under “Product Development”, but one of the applications is in organ transplant. Prior to the Covid-19 pandemic, the average time that a patient waits on a kidney transplant waiting list in the UK is typically 30 months. In the USA, it is over 4 years. At the same time, many potential transplant organs are rejected because they appear to be of poor quality. The project aims to develop a device for perfusing donated organs with oxygenated blood to maintain their viability ex-vivo. The device will allow many previously rejected organs to be salvaged and will also improve the success rate for all transplanted organs.
The project consolidates Haemair developments with work previously undertaken by our 100% subsidiary Haemaflow Ltd.
November 20, 2020 4:46 pm
Haemair have also recently completed a project supported by a grant of £219,017 awarded
Innovate UK to develop a device to treat the comorbidities of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI). Haemair lead the project and were supported by Derbyshire partners Automated Technologies Ltd. Acute Kidney injury arises commonly in ARDS patients; recent studies indicate that over 40% of patients suffering Covid-19 induced ARDS also suffer AKI. In other forms of ARDS (afflicting around 30,000 UK patients annually), the proportion is up to 50%. The mortality rate for patients suffering these comorbidities can be as high as 85%. Hence, the new technology has the potential to save thousands of lives.
The project is described more fully under “Project Development”.